Anti Translation Eucaryotic Factor (eIF3b) Antibody PDF Print E-mail

A valuable research tool that demonstrates significant potential with regards to the characterization of proliferating cells that over express eIF3

Antibody from this clone recognizes the RNA recognizing motif (RRM) of subunit b of the eukaryotic Initiation Factor 3 (eIF3) molecule. eIF3 binds specifically to mRNA and some viral RNA genomes and plays an essential role in the translation initiation process. This antibody shows significant potential with regards to the characterization of proliferating cells that over express eIF3.

anticorps2.jpg anticorps1.jpg souris.jpg

 

Features/Benefits

  • Monoclonal Antibody
    • Highly targeted
  • Validated for use in immunoblotting
    /immunohistochemistry/cytochemistry
    • Suitable for use within a research environment
  • UVHCI (Unit of Virus Host Cell Interactions), laboratory renowned at a European level S
    • Specialists in the understanding of EBV biology, the team is able to
      provide a high level of technical support.

Applications

This research/diagnostic tool shows significant potential in the following fields:

  • Fundamental Virology
  • Cancer Research

Scientific Data

Name: eIF3b MRR
Specificity: Cell proliferation marker (for over expression of eIF3. Recognizing the RNA recognizing motif (RRM) of eIF3.
Clone:
2D3D9
Host species Mouse
Ig subclass Mouse monoclonal IgGs
Applications The antibody is effective in immunoblotting, cytochemistry, immunohistochemistry
Culture medium RPMI 1640 with FCS GIBCO (Invitrogene) 10%

 














Commercial Opportunities

This technology is available to license to organisations working in the field of monoclonal antibody distribution.

Contact

Technology Transfer
Pascale Grenard-Ecuyer
+33 476 00 78 34
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

 

TECHNOLOGY FOCUS

TESTIMONIALS

"Thanks to the Optical Imaging Platform we have been able to carry out preliminary trials" JS Sun, DNA Therapeutics
Read more...